ArticleEBioMedicine2026
Mechanistic analysis of an IRF7-dependent pathway in virus-induced fibrosis in chronic lung allograft dysfunction.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundChronic lung allograft dysfunction (CLAD) significantly limits long-term survival of lung transplant recipients, with viral infections acting as critical contributors to its pathogenesis. The mechanisms linking viral infections to CLAD-associated airway fibrosis remain incompletely understood. This study investigates the role of the type I interferon (IFN) master regulator IRF7 in virus-induced airway fibrogenesis.
methodsCLAD (Bronchiolitis obliterans syndrome (BOS)), Stable LTx, and non-transplanted lung tissues were analysed by spatial transcriptomics (GeoMx; n = 5 CLAD (BOS), n = 3 Stable LTx, n = 3 controls), Western blotting, and immunostaining. Primary bronchial epithelial cells in air-liquid-interface (ALI) culture and a human precision-cut lung slice (PCLS) ex vivo model were exposed to Influenza A virus (IAV) with or without IRF7 silencing, IL-33 blockade, or MMP-9 inhibition. Group comparisons used Mann-Whitney tests and one-way ANOVA with Tukey's post hoc test; spatial differential expression used linear models with Benjamini-Hochberg correction (α = 0.05).
findingsSpatial transcriptomics identified enrichment of IFN-stimulated genes including IRF7, STAT1, IFI44L, and GBP1 in the CLAD (BOS) epithelial compartment alongside antiviral effector genes (DDX58, TLR3) and pro-fibrotic programmes (TGFB1, SMAD2/3, ACTA2). Western blotting confirmed significantly increased IRF7 and phosphorylated IRF7 with airway-centric distribution in CLAD (BOS) (p < 0.01; n = 3-4). IAV exposure upregulated IRF7, α-SMA, SMAD2/3, and soluble collagen in ALI cultures (all p < 0.01; n = 3-6); IRF7 silencing attenuated these markers and reduced virus-induced IL-33 at mRNA and protein levels (p < 0.05). IL-33 blockade independently reduced α-SMA (p < 0.05), confirming IL-33 as a downstream IRF7 mediator. IAV increased MMP-9 secretion (p < 0.0001); IRF7 or IL-33 blockade attenuated MMP-9, while MMP-9 inhibition reduced α-SMA (p < 0.0001). All findings were replicated in human PCLS (p < 0.05; n = 5-6).
interpretationThese findings delineate an IRF7-IL-33-MMP-9 axis linking viral infections to airway fibrogenesis, offering mechanistic insight into CLAD (BOS) pathogenesis. Therapeutic targeting of this pathway may mitigate fibrotic remodelling in lung transplant recipients.
fundingNIH 1R01HL161620 (N.S.S.). Caredx IIT (N.S.S).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.